Figure 1From: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsMean and median ratios to baseline for VEGF (panel a), sVEGFR-2 (panel b), and PlGF (panel c) at each timepoint in various treatment cycles (SEM = Standard Error of the Mean). Mean and median ratios to baseline for VEGF (panel a), sVEGFR-2 (panel b), and PlGF (panel c) at each timepoint in various treatment cycles (SEM = Standard Error of the Mean). Soluble protein plasma level ratios relative to baseline (cycle 1, day 1) are plotted as a series of timepoints, with the baseline values normalized to 1. C(N)D(N) = cycle number, day number (e.g., C1D28 = cycle 1, day 28). The number of values available is listed in parentheses below each time point. The rise and fall of these proteins in accordance with the 4 weeks-on/2 weeks-off sunitinib dosing regimen is indicative of a drug-dependent effect.Back to article page